<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177175</url>
  </required_header>
  <id_info>
    <org_study_id>14-099</org_study_id>
    <nct_id>NCT02177175</nct_id>
  </id_info>
  <brief_title>Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification</brief_title>
  <official_title>Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effects, good and/or bad, of a beta blocker&#xD;
      (carvedilol) on heart function during treatment with anti-HER2 medication(s) including&#xD;
      trastuzumab (Herceptin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II placebo-controlled study will evaluate the effect of carvedilol, compared to&#xD;
      placebo, on anthracycline/anti-HER2 therapy induced left ventricular dysfunction in patients&#xD;
      with HER2-positive breast cancer who are receiving adjuvant or neoadjuvant therapy. All&#xD;
      patients will undergo routine cardiac surveillance with 2D echocardiograms per standard of&#xD;
      care at multiple time points which will align as closely as possible to the following:&#xD;
      pre-anthracycline (baseline), pre-anti-HER2 therapy, and 3, 6, 9, and 12 months (+/- 4 weeks)&#xD;
      after initiation of anti-HER2 therapy. In the case that standard of care echocardiograms are&#xD;
      not done at these time points, either due to a delay in anti-cancer therapy or due to the&#xD;
      patient's medical condition, the principal investigator will determine if the standard of&#xD;
      care echocardiogram may be used in lieu of one of the time points listed. Additional speckle&#xD;
      tracking strain analysis will be performed on these echocardiograms, and blood specimens will&#xD;
      be drawn at several time points for biomarker analysis.&#xD;
&#xD;
      After completion of anthracycline treatment and prior to initiation of anti-HER2 therapy, 32&#xD;
      patients with abnormal myocardial strain, defined as global longitudinal strain &lt; 19% or %&#xD;
      change from baseline by &gt; 11%, will be randomized in a 1:1 ratio to carvedilol versus&#xD;
      placebo. Carvedilol will be administered twice daily for approximately 1 year OR until the&#xD;
      end of anti-HER2 therapy, if it is discontinued prior to 1 year. Treatment in both carvedilol&#xD;
      and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after&#xD;
      randomization to a goal dose of 25mg twice daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2014</start_date>
  <completion_date type="Actual">June 24, 2021</completion_date>
  <primary_completion_date type="Actual">June 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum change in LVEF</measure>
    <time_frame>at months 3, 6, 9, and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of abnormal LVEF</measure>
    <time_frame>at months 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Non-metastatic histologically confirmed primary invasive breast carcinoma&#xD;
&#xD;
          -  Pathologically confirmed HER2-positive breast cancer&#xD;
&#xD;
          -  Scheduled to receive anthracycline chemotherapy followed by anti-HER2 therapy at MSKCC&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Willing and able to comply with the requirements of the protocol&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
        For Aim 2, all patients must meet the following criteria:&#xD;
&#xD;
          -  Meet all inclusion criteria above&#xD;
&#xD;
               -  LVEF &gt; 50%&#xD;
&#xD;
          -  Abnormal global longitudinal strain (&lt;19%, or a % decrease of ≥ 11% from baseline)&#xD;
             prior to initiation of planned anti-HER2 therapy&#xD;
&#xD;
          -  Heart rate ≥ 50 beats per minute&#xD;
&#xD;
          -  Sitting systolic blood pressure &gt; 90 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are to be excluded from randomization for Aim 2 of this study if they meet&#xD;
             any of the following criteria:&#xD;
&#xD;
          -  Current treatment with ACE-inhibitors or beta blockers&#xD;
&#xD;
          -  Allergies or inability to tolerate beta blockers previously due to bradycardia,&#xD;
             hypotension, or AV block.&#xD;
&#xD;
          -  Known history of NCI CTCAE (Version 4.0) Grade ≥ 2 symptomatic CHF, myocardial&#xD;
             infarction within 12 months prior to randomization, significant symptoms (Grade ≥ 3)&#xD;
             relating to left ventricular dysfunction, significant (moderate or severe) valvular&#xD;
             disease, or significant cardiac arrhythmia (Grade ≥ 3)&#xD;
&#xD;
          -  Pre-menopausal women without a negative serum or urine pregnancy test within 4 weeks&#xD;
             of starting treatment&#xD;
&#xD;
          -  Enrollment in a therapeutic intervention trial in the Breast Medicine service&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carvedilol</keyword>
  <keyword>Anthracycline</keyword>
  <keyword>HER2</keyword>
  <keyword>14-099</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

